Sino Biopharmaceutical co-led the oncology treatment developer's latest round, in which it raised over $91m in funding.

Treadwell Therapeutics, US-based small molecule cancer therapy developer exploiting research from University Health Network, has secured more than $91m in a series B round co-led by pharmaceutical firm Sino Biopharmaceutical with investment adviser 3W Fund Management. The round also featured venture creation firm Tio Bioventures, Prosperous Alliance, Alpha Win Capital, Fortune Ocean Growth Fund, private…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.